Anti-donor immune responses elicited by allogeneic mesenchymal stem cells: What have we learned so far

Immunology and Cell Biology

Volumn 91, Issue 1, 2013, Pages 40-51

  Griffin, Matthew D ^a   Ryan, Aideen E ^a   Alagesan, Senthilkumar ^a   Lohan, Paul ^a   Treacy, Oliver ^a   Ritter, Thomas ^a  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

allogeneic; immune response; mesenchymal stem cells; T cells; transplant

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 1BETA; TUMOR NECROSIS FACTOR ALPHA;

B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL SURVIVAL; CELLULAR IMMUNITY; DONOR; GRAFT REJECTION; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; IN VIVO STUDY; MESENCHYMAL STEM CELL; NATURAL KILLER CELL; NONHUMAN; REVIEW; T LYMPHOCYTE;

ANIMALS; ANTIBODY FORMATION; B-LYMPHOCYTES; GRAFT REJECTION; HUMANS; IMMUNITY, CELLULAR; ISOANTIGENS; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; T-LYMPHOCYTES; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS; UNRELATED DONORS;

ANIMALIA;

EID: 84872139846     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2012.67     Document Type: Review

References (86)

1. Starzl T. History of clinical transplantation. World J Surg 2000; 24: 759-782. (Pubitemid 30437472)
2. Tilney NL. Transplantation and its biology: From fantasy to routine. J Appl Physiol 2000; 89: 1681-1689.
3. Wood KJ, Goto R. Mechanisms of rejection: Current perspectives. Transplantation 2012; 93: 1-10.
4. Nankivell BJ, Alexander SI. Rejection of the kidney allograft. N Engl JMed 2010; 363: 1451-1462.
5. Chong AS, Alegre M-L. The impact of infection and tissue damage in solid-organ transplantation. Nat Rev Immunol 2012; 12: 459-471.
6. Ferrara JL, Levine JE, Reddy P, Holler E. Graft-versus-host disease. Lancet 2009; 373: 1550-1561.
7. Leventhal J, Abecassis M, Miller J, Gallon L, Ravindra K, Tollerud DJ et al. Chimerism and tolerance without GVHD or engraftment syndrome in HLA-mismatched combined kidney and hematopoietic stem cell transplantation. Science Transl Med 2012; 4: 124-128.
8. Everly MJ, Terasaki PI. Monitoring and treating posttransplant human leukocyte antigen antibodies. Hum Immunol 2009; 70: 655-659.
9. Gloor J, Cosio F, Lager DJ, Stegall MD. The spectrum of antibody-mediated renal allograft injury: Implications for treatment. Am J Transplant 2008; 8: 1367-1373. (Pubitemid 351989489)
10. Vats A, Bielby RC, Tolley NS, Nerem R, Polak JM. Stem cells. Lancet 2005; 366: 592-602. (Pubitemid 41149084)
11. Robinton DA, Daley GQ. The promise of induced pluripotent stem cells in research and therapy. Nature 2012; 481: 295-305.
12. Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol 2008; 8: 726-736.
13. Griffin MD, Ritter T, Mahon B. Immunological aspects of allogeneic mesenchymal stem cell therapy. Hum Gene Ther 2010; 21: 1641-1655.
14. Brooke G, Cook M, Blair C, Han R, Heazlewood C, Jones B et al. Therapeutic applications of mesenchymal stromal cells. Semin Cell Dev Biol 2007; 18: 846-858. (Pubitemid 350138458)
15. Ankrum J, Karp JM. Mesenchymal stem cell therapy: Two steps forward, one step back. Trends Mol Med 2010; 16: 203-209.
16. Caplan AI. Why are MSCs therapeutic? New data: New insight. J Pathol 2009; 217: 318-324.
17. Dazzi F, Lopes L, Weng L. Mesenchymal stromal cells: A key player in 'innate tolerance'? Immunology 2012; 137: 206-213.
18. Nauta AJ, Fibbe WE. Immunomodulatory properties of mesenchymal stromal cells. Blood 2007; 110: 3499-3506. (Pubitemid 350159613)
19. Prockop DJ, Youn Oh J. Mesenchymal stem/stromal sells (MSCs): Role as guardians of inflammation. Mol Ther 2012; 20: 14-20.
20. McKernan R, McNeish J, Smith D. Pharma's developing interest in stem cells. Cell Stem Cell 2010; 6: 517-520.
21. English K, French A, Wood KJ. Mesenchymal stromal cells: Facilitators of successful transplantation? Cell Stem Cell 2010; 7: 431-442.
22. Afzali B, Lombardi G, Lechler RI. Pathways of major histocompatibility complex allorecognition. Curr Opin Organ Transplant 2008; 13: 109.
23. Montecalvo A, Shufesky WJ, Beer Stolz D, Sullivan MG, Wang Z, Divito SJ et al. Exosomes as a short-range mechanism to spread alloantigen between dendritic cells during T cell allorecognition. J Immunol 2008; 180: 3081-3090.
24. Duijvestein M, Wildenberg ME, Welling MM, Hennink S, Molendijk I, van Zuylen VL et al. Pretreatment with interferon-gamma enhances the therapeutic activity of mesenchymal stromal cells in animal models of colitis. Stem Cells 2011; 29: 1549-1558.
25. English K, Barry FP, Field-Corbett CP, Mahon BP. IFN-g and TNF-a differentially regulate immunomodulation by murine mesenchymal stem cells. Immunol Lett 2007; 110: 91-100. (Pubitemid 46830943)
26. Sheng H, Wang Y, Jin Y, Zhang Q, Zhang Y, Wang L et al. A critical role of IFNgamma in priming MSC-mediated suppression of T cell proliferation through up-regulation of B7-H1. Cell Res 2008; 18: 846-857.
27. Polchert D, Sobinsky J, Douglas G, Kidd M, Moadsiri A, Reina E et al. IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease. Eur J Immunol 2008; 38: 1745-1755.
28. Badillo AT, Beggs KJ, Javazon EH, Tebbets JC, Flake AW. Murine bone marrow stromal progenitor cells elicit an in vivo cellular and humoral alloimmune response. Biol Blood Marrow Transplant 2007; 13: 412-422. (Pubitemid 46421896)
29. Duffy MM, Ritter T, Ceredig R, Griffin MD. Mesenchymal stem cell effects on T-cell effector pathways. Stem Cell Res Ther 2011; 2: 34.
30. Duffy MM, Pindjakova J, Hanley SA, McCarthy C, Weidhofer GA, Sweeney EM et al. Mesenchymal stem cell inhibition of T-helper 17 cell-differentiation is triggered by cell-cell contact and mediated by prostaglandin E2 via the EP4 receptor. Eur J Immunol 2011; 41: 2840-2851.
31. Ghannam S, Bouffi C, Djouad F, Jorgensen C, Noel D. Immunosuppression by mesenchymal stem cells: Mechanisms and clinical applications. Stem Cell Res Ther 2010; 1: 2.
32. Kavanagh H, Mahon BP. Allogeneic mesenchymal stem cells prevent allergic airway inflammation by inducing murine regulatory T cells. Allergy 2011; 66: 523-531.
33. Rasmusson I, Ringdén O, Sundberg B, LeBlanc K. Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. Transplantation 2003; 76: 1208-1213. (Pubitemid 37339646)
34. Angoulvant D, Clerc A, Benchalal S, Galambrun C, Farre A, Bertrand Y et al. Human mesenchymal stem cells suppress induction of cytotoxic response to alloantigens. Biorheology 2004; 41: 469-476. (Pubitemid 39277103)
35. English K, Barry FP, Mahon BP. Murine mesenchymal stem cells suppress dendritic cell migration, maturation and antigen presentation. Immunol Lett 2008; 115: 50-58. (Pubitemid 350298590)
36. Nauta AJ, Kruisselbrink AB, Lurvink E, Willemze R, Fibbe WE. Mesenchymal stem cells inhibit generation and function of both CD34+-derived and monocyte-derived dendritic cells. J Immunol 2006; 177: 2080-2087. (Pubitemid 44200965)
37. Biancone L, Bruno S, Deregibus MC, Tetta C, Camussi G. Therapeutic potential of mesenchymal stem cell-derived microvesicles. Nephrol Dial Transplant 2012; 27: 3037-3042.
38. Strassburg S, Hodson NW, Hill PI, Richardson SM, Hoyland JA. Bi-directional exchange of membrane components occurs during co-culture of mesenchymal stem cells and nucleus pulposus cells. PLoS One 2012; 7: E33739.
39. Tarlinton DM, Batista F, Smith KGC. The B-cell response to protein antigens in immunity and transplantation. Transplantation 2008; 85: 1698-1704.
40. Stegall MD, Dean PG, Gloor J. Mechanisms of alloantibody production in sensitized renal allograft recipients. Am J Transplant 2009; 9: 998-1005.
41. Franquesa M, Hoogduijn MJ, Bestard O, Grinyó JM. Immunomodulatory effect of mesenchymal stem cells on B cells. Front Immunol 2012; 3: 212.
42. Tabera S, Pérez-Simón JA, Díez-Campelo Ma, Sánchez-Abarca LI, Blanco B, López A et al. The effect of mesenchymal stem cells on the viability, proliferation and differentiation of B-lymphocytes. Haematologica 2008; 93: 1301-1309.
43. Rasmusson I, Le Blanc K, Sundberg B, Ringdén O. Mesenchymal stem cells stimulate antibody secretion in human B cells. Scand J Immunol 2007; 65: 336-343. (Pubitemid 46481102)
44. Villard J. The role of natural killer cells in human solid organ and tissue transplantation. J Innate Immunity 2011; 3: 395-402.
45. Hoglund P, Brodin P. Current perspectives of natural killer cell education by MHC class I molecules. Nat Rev Immunol 2010; 10: 724-734.
46. Spaggiari GM, Capobianco A, Becchetti S, Mingari MC, Moretta L. Mesenchymal stem cell-natural killer cell interactions: Evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood 2006; 107: 1484-1490. (Pubitemid 43242385)
47. Hoogduijn M, Roemeling-van Rhijn M, Korevaar S, Engela AU, Weimar W, Baan CC. Immunological aspects of allogeneic and autologous mesenchymal stem cell therapies. Hum Gene Ther 2012; 22: 1587-1591.
48. Poggi A, Prevosto C, Massaro AM, Negrini S, Urbani S, Pierri I et al. Interaction between human NK cells and bone marrow stromal cells induces NK cell triggering: Role of NKp30 and NKG2D receptors. J Immunol 2005; 175: 6352-6360. (Pubitemid 41598875)
49. Camp D, Loeffler D, Farrah D, Borneman JN, LeWitt PA. Cellular immune response to intrastriatally implanted allogeneic bone marrow stromal cells in a rat model of Parkinson's disease. J Inflamm 2009; 6: 17.
50. Chen L, Tredget EE, Liu C, Wu Y. Analysis of allogenicity of mesenchymal stem cells in engraftment and wound healing in mice. PLoS One 2009; 4: E7119.
51. Zangi L, Margalit R, Reich-Zeliger S, Bachar-Lustig E, Beilhack A, Negrin R et al. Direct imaging of immune rejection and memory induction by allogeneic mesenchymal stromal cells. Stem Cells 2009; 27: 2865-2874.
52. Togel F, Cohen A, Zhang P, Yang Y, Hu Z, Westenfelder C. Autologous and allogeneic marrow stromal cells are safe and effective for the treatment of acute kidney injury. Stem Cells Dev 2009; 18: 475-485.
53. Nauta AJ, Westerhuis G, Kruisselbrink AB, Lurvink EG, Willemze R, Fibbe WE. Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting. Blood 2006; 108: 2114-2120. (Pubitemid 44395028)
54. Rafei M, Birman E, Forner K, Galipeau J. Allogeneic mesenchymal stem cells for treatment of experimental autoimmune encephalomyelitis. Mol Ther 2009; 17: 1799-1803.
55. Huang X-P, Sun Z, Miyagi Y, McDonald Kinkaid H, Zhang L, Weisl RD et al. Differentiation of allogeneic mesenchymal stem cells induces immunogenicity and limits their long-term benefits for myocardial repair/clinical perspective. Circulation 2010; 122: 2419-2429.
56. Quevedo HC, Hatzistergos KE, Oskouei BN, Feighenbaum GS, Rodriguez JE, Valdes D et al. Allogeneic mesenchymal stem cells restore cardiac function in chronic ischemic cardiomyopathy via trilineage differentiating capacity. Proc Natl Acad Sci USA 2009; 106: 14022-14027.
57. Nemeth K, Leelahavanichkul A, Yuen PS, Mayer B, Parmelee A, Doi K et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E2-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat Med 2009; 15: 42-49.
58. Beggs KJ, Lyubimov A, Borneman JN, Bartholomew A, Moseley A, Dodds R et al. Immunologic consequences of multiple, high-dose administration of allogeneic mesenchymal stem cells to baboons. Cell Transplant 2006; 15: 711-721. (Pubitemid 46095254)
59. Eliopoulos N, Stagg J, Lejeune L, Pommey S, Galipeau J. Allogeneic marrow stromal cells are immune rejected by MHC class I-and class II-mismatched recipient mice. Blood 2005; 106: 4057-4065. (Pubitemid 41775910)
60. Isakova IA, Dufour J, Lanclos C, Bruhn J, Phinney DG. Cell-dose-dependent increases in circulating levels of immune effector cells in rhesus macaques following intracranial injection of allogeneic MSCs. Exp Hematol 2010; 38: 957-967.
61. Poncelet AJ, Vercruysse J, Saliez A, Gianello P. Although pig allogeneic mesenchymal stem cells are not immunogenic in vitro, intracardiac injection elicits an immune response in vivo. Transplantation 2007; 83: 783-790. (Pubitemid 46569198)
62. Seifert M, Stolk M, Polenz D, Volk HD. Detrimental effects of rat mesenchymal stromal cell pre-treatment in a model of acute kidney rejection. Front Immunol 2012; 3: 202.
63. Ge W, Jiang J, Baroja ML, Arp J, Zassoko R, Liu W et al. Infusion of mesenchymal stem cells and rapamycin synergize to attenuate alloimmune responses and promote cardiac allograft tolerance. Am J Transplant 2009; 9: 1760-1772.
64. Ge W, Jiang J, Arp J, Liu W, Garcia B, Wang H. Regulatory T-cell generation and kidney allograft tolerance induced by mesenchymal stem cells associated with indoleamine 2,3-dioxygenase expression. Transplantation 2010; 90: 1312-1320.
65. Casiraghi F, Azzollini N, Todeschini M, Cavinato RA, Cassis P, Solini S et al. Localization of mesenchymal stromal cells dictates their immune or proinflammatory effects in kidney transplantation. Am J Transplant 2012; 12: 2373-2383.
66. Casiraghi F, Azzollini N, Cassis P, Imberti B, Morigi M, Cugini D et al. Pretransplant infusion of mesenchymal stem cells prolongs the survival of a semiallogeneic heart transplant through the generation of regulatory t cells. J Immunol 2008; 181: 3933-3946.
67. Lechler RI, Garden OA, Turka LA. The complementary roles of deletion and regulation in transplantation tolerance. Nat Rev Immunol 2003; 3: 147-158. (Pubitemid 37328692)
68. Cai J, Terasaki PI. Post-transplantation antibody monitoring and HLA antibody epitope identification. Curr Opin Immunol 2008; 20: 602-606.
69. Poncelet AJ, Nizet Y, Vercruysse J, Hiel AL, Saliez A, Gianello P. Inhibition of humoral response to allogeneic porcine mesenchymal stem cell with 12 days of tacrolimus. Transplantation 2008; 86: 1586-1595.
70. Schu S, Nosov M, O'Flynn L, Shaw G, Treacy O, Barry F et al. Immunogenicity of allogeneic mesenchymal stem cells. J Cell Mol Med 2012; 16: 2094-2103.
71. Krampera M, Cosmi L, Angeli R, Pasini A, Liotta F, Andreini A et al. Role for interferongamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells 2006; 24: 386-398. (Pubitemid 44464808)
72. Ren G, Zhang L, Zhao X, Zhang L, Zhang J, Roberts AI et al. Mesenchymal stem cellmediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2008; 2: 141-150. (Pubitemid 351181031)
73. Wagner J, Kean T, Young R, Dennis JE, Caplan AI. Optimizing mesenchymal stem cellbased therapeutics. Curr Opin Biotechnol 2009; 20: 531-536.
74. Krampera M. Mesenchymal stromal cell 'licensing': A multistep process. Leukemia 2011; 25: 1408-1414.
75. Chan WK, Lau AS, Li JC, Law HK, Lau YL, Chan GC. MHC expression kinetics and immunogenicity of mesenchymal stromal cells after short-term IFN-g challenge. Exp Hematol 2008; 36: 1545-1555.
76. Cho PS, Messina DJ, Hirsh EL, Chi N, Goldman SN, Lo DP et al. Immunogenicity of umbilical cord tissue-derived cells. Blood 2008; 111: 430-438.
77. Pittenger MF, Martin BJ. Mesenchymal stem cells and their potential as cardiac therapeutics. Circ Res 2004; 95: 9-20. (Pubitemid 38931831)
78. Khojasteh A, Behnia H, Dashti SG, Stevens M. Current trends in mesenchymal stem cell application in bone augmentation: A review of the literature. J Oral Maxillofacial Surg 2012; 70: 972-982.
79. Kotobuki N, Katsube Y, Katou Y, Tadokoro M, Hirose M, Ohgushi H. In vivo survival and osteogenic differentiation of allogeneic rat bone marrow mesenchymal stem cells (MSCs). Cell Transplant 2008; 17: 705-712.
80. Liu H, Kemeny DM, Heng BC, Ouyang HW, Melendez AJ, Cao T. The immunogenicity and immunomodulatory function of osteogenic cells differentiated from mesenchymal stem cells. J Immunol 2006; 176: 2864-2871.
81. Williams AR, Hare JM. Mesenchymal stem cells. Circ Res 2011; 109: 923-940.
82. Dai W, Hale SL, Martin BJ, Kuang JQ, Dow JS, Wold LE et al. Allogeneic mesenchymal stem cell transplantation in postinfarcted rat myocardium. Circulation 2005; 112: 214-223. (Pubitemid 40982304)
83. Bernardo ME, Pagliara D, Locatelli F. Mesenchymal stromal cell therapy: A revolution in regenerative medicine. Bone Marrow Transplant 2012; 47: 164-171.
84. Wang S, Xuebin Q, Zhao R. Clinical applications of mesenchymal stem cells. J Hematol Oncol 2012; 5: 19.
85. Hare JM, Traverse JH, Henry TD, Dib N, Strumpf RK, Schulman SP et al. A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (Prochymal) after acute myocardial infarction. J Am Coll Cardiol 2009; 54: 2277-2286.
86. Zupanska B, Uhrynowska M, Michur H, Maslanka K, Zajko M. Transfusion-related acute lung injury and leucocyte-reacting antibodies. Vox Sang 2007; 93: 70-77. (Pubitemid 46850710)